Effects of CYP3A4 Inhibitors Ketoconazole and Verapamil and the CYP3A4 Inducer Rifampicin on the Pharmacokinetic Parameters of Fostamatinib: Results from In Vitro and Phase I Clinical Studies
Crossref DOI link: https://doi.org/10.1007/s40268-015-0118-4
Published Online: 2016-01-06
Published Print: 2016-03
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Martin, Paul
Gillen, Michael
Millson, David
Oliver, Stuart
Brealey, Clive
Grossbard, Elliott B.
Baluom, Muhammad
Lau, David
Sweeny, David
Mant, Tim
Craven, Kelli
Funding for this research was provided by:
AstraZeneca
License valid from 2016-01-06